PureTech Health plc(PRTC)Earnings, Financials & Key Ratios
PRTC•NASDAQ
$17.01
$41M mkt cap·Price updated May 6, 2026
AboutPureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Show more
- Revenue$5M-3.5%
- EBITDA-$95M+28.2%
- Net Income-$110M-305.1%
- EPS (Diluted)-46.00-2400.0%
- Gross Margin100%+284.1%
- EBITDA Margin-2042.84%+25.6%
- Operating Margin-2114.72%+25.0%
- Net Margin-2355.42%-312.5%
- ROE-30.76%-348.9%
- ROIC-66.87%-44.8%
- Debt/Equity0.06+17.9%
- Interest Coverage-1.42-142.2%
PRTC Key Insights
PureTech Health plc (PRTC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Share count reduced 91.1% through buybacks
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Sales declining 11.0% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PRTC Price & Volume
PureTech Health plc (PRTC) stock price & volume — 10-year historical chart
Loading chart...
PRTC Growth Metrics
PureTech Health plc (PRTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-8.83%
5 Years-10.99%
3 Years30.63%
TTM-53.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM52.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1176.19%
Return on Capital
10 Years-44.32%
5 Years-22.86%
3 Years-21.6%
Last Year-18.77%
PRTC Recent Earnings
PureTech Health plc (PRTC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (80%)●Beat Revenue 3/12 qtrs (30%)
Q2 2026Latest
Apr 29, 2026EPS
$26.90
Est $1.94
-1286.6%
Revenue
$3M
Est $2M
+47.2%
Q3 2025
Aug 28, 2025EPS
$1.86
Est $2.04
+8.9%
Revenue
$2M
Est $27M
-93.2%
Q2 2025
Apr 30, 2025EPS
$0.35
Est $2.83
+112.5%
Revenue
$4M
Est $30M
-86.7%
Q3 2024
Aug 28, 2024EPS
$0.15
Est $3.03
+94.9%
Revenue
$288,000
Est $8M
-96.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $26.90vs $1.94-1286.6% | $3Mvs $2M+47.2% |
| Q3 2025 | Aug 28, 2025 | $1.86vs $2.04+8.9% | $2Mvs $27M-93.2% |
| Q2 2025 | Apr 30, 2025 | $0.35vs $2.83+112.5% | $4Mvs $30M-86.7% |
| Q3 2024 | Aug 28, 2024 | $0.15vs $3.03+94.9% | $288,000vs $8M-96.2% |
Based on last 12 quarters of dataView full earnings history →
PRTC Peer Comparison
PureTech Health plc (PRTC) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ROIV | 20.91B | 28.82 | -120.08 | -11.19% | -60.8% | -16.27% | 0.02 | |
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 | |
 CMPS | 937.8M | 9.76 | -3.17 | -335.93% | ||||
 RXRX | 1.53B | 3.43 | -2.38 | 26.92% | -8.44% | -54.32% | 0.07 | |
 ABSI | 924.91M | 5.95 | -7.08 | -38.24% | -41.14% | -59.68% | 0.03 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 |
Compare PRTC vs Peers
PureTech Health plc (PRTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRTC Income Statement
PureTech Health plc (PRTC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 650K | 16.37M | 8.69M | 8.34M | 9.98M | 2.09M | 3.33M | 4.83M | 4.66M |
| Revenue Growth % | -85.33% | 2418.62% | -46.93% | -3.99% | 19.64% | -79.06% | 59.33% | 44.98% | -3.5% |
| Cost of Goods Sold | 71.03M | 77.4M | 85.85M | 0 | 110.47M | 152.43M | 4.93M | 0 | 0 |
| COGS % of Revenue | 10928.46% | 472.8% | 988.12% | - | 1107.03% | 7293.44% | 148.14% | - | - |
| Gross Profit | -70.39M▲ 0% | -61.03M▲ 13.3% | -77.16M▼ 26.4% | 8.34M▲ 110.8% | -100.49M▼ 1304.8% | -136.81M▼ 36.1% | -1.6M▲ 98.8% | 1.26M▲ 178.4% | 4.66M▲ 270.6% |
| Gross Margin % | -10828.46% | -372.8% | -888.12% | 100% | -1007.03% | -6546.17% | -48.14% | 26.04% | 100% |
| Gross Profit Growth % | -2560.15% | 13.29% | -26.43% | 110.81% | -1304.8% | -36.15% | 98.83% | 178.42% | 270.64% |
| Operating Expenses | 116.07M | 120.39M | 144.09M | 127.87M | 160.26M | 60.99M | 54.55M | 140.41M | 103.18M |
| OpEx % of Revenue | 17856.92% | 735.39% | 1658.46% | 1533.05% | 1605.99% | 2918.28% | 1638.26% | 2908.24% | 2214.72% |
| Selling, General & Admin | 46.28M | 24.43M | 34.89M | 26.5M | 30.76M | 35.67M | 48.36M | 27.49M | 20.65M |
| SG&A % of Revenue | 7120.46% | 149.2% | 401.59% | 317.67% | 308.26% | 1706.65% | 1452.31% | 569.41% | 443.29% |
| Research & Development | 71.67M | 57.29M | 65.17M | 61.19M | 81.52M | 116.11M | 96.23M | 54.28M | 45.74M |
| R&D % of Revenue | 11026.46% | 349.97% | 750.07% | 733.56% | 816.93% | 5555.65% | 2889.94% | 1124.28% | 981.82% |
| Other Operating Expenses | 14K | -278K | 44.03M | 40.19M | 47.98M | -90.79M | -90.04M | 58.64M | 36.79M |
| Operating Income | -115.42M▲ 0% | -104.02M▲ 9.9% | -135.4M▼ 30.2% | -119.53M▲ 11.7% | -150.28M▼ 25.7% | -197.81M▼ 31.6% | -146.2M▲ 26.1% | -136.09M▲ 6.9% | -98.53M▲ 27.6% |
| Operating Margin % | -17756.92% | -635.39% | -1558.46% | -1433.05% | -1505.98% | -9464.45% | -4390.36% | -2818.87% | -2114.72% |
| Operating Income Growth % | -56.12% | 9.88% | -30.17% | 11.72% | -25.73% | -31.62% | 26.09% | 6.91% | 27.61% |
| EBITDA | -113.32M | -101.24M | -128.73M | -112.88M | -143.04M | -188.91M | -141.27M | -132.52M | -95.18M |
| EBITDA Margin % | -17434% | -618.42% | -1481.74% | -1353.27% | -1433.45% | -9038.95% | -4242.22% | -2744.9% | -2042.84% |
| EBITDA Growth % | -56.61% | 10.66% | -27.16% | 12.32% | -26.73% | -32.07% | 25.22% | 6.19% | 28.18% |
| D&A (Non-Cash Add-back) | 2.1M | 2.78M | 6.67M | 6.66M | 7.24M | 8.89M | 4.93M | 3.57M | 3.35M |
| EBIT | -70.01M | -68.05M | 481.12M | 56.03M | 19.46M | -197.81M | -16.56M | 33.81M | -65.15M |
| Net Interest Income | -8.46M | -11.45M | 260K | -1.76M | -4.5M | 1.85M | 2.52M | 12.63M | -32.73M |
| Interest Income | 1.75M | 3.36M | 4.36M | 1.18M | 214K | 5.8M | 16.01M | 22.67M | 13.05M |
| Interest Expense | 10.21M | 14.81M | 4.1M | 2.95M | 4.71M | 3.95M | 13.49M | 10.04M | 45.78M |
| Other Income/Expense | 44.71M | 35.58M | 613.87M | 138.5M | 91.33M | 105.02M | 110.1M | 159.87M | -12.4M |
| Pretax Income | -70.71M▲ 0% | -68.44M▲ 3.2% | 478.47M▲ 799.1% | 18.97M▼ 96.0% | -58.95M▼ 410.8% | -92.78M▼ 57.4% | -36.1M▲ 61.1% | 23.77M▲ 165.9% | -110.93M▼ 566.6% |
| Pretax Margin % | -10878.62% | -418.04% | 5507.3% | 227.42% | -590.77% | -4439.38% | -1084.17% | 492.42% | -2380.92% |
| Income Tax | -14K | 2.22M | 112.41M | 14.4M | 3.76M | -55.72M | 30.52M | -4.01M | -842K |
| Effective Tax Rate % | 0.02% | -3.25% | 23.49% | 75.92% | -6.37% | 60.05% | -84.55% | -16.86% | 0.76% |
| Net Income | 30.87M▲ 0% | -43.65M▼ 241.4% | 421.14M▲ 1064.7% | 5.99M▼ 98.6% | -60.56M▼ 1111.8% | -50.35M▲ 16.8% | -65.7M▼ 30.5% | 53.51M▲ 181.4% | -109.74M▼ 305.1% |
| Net Margin % | 4749.08% | -266.65% | 4847.42% | 71.75% | -606.85% | -2409.33% | -1972.88% | 1108.33% | -2355.42% |
| Net Income Growth % | 163.27% | -241.42% | 1064.73% | -98.58% | -1111.83% | 16.85% | -30.47% | 181.45% | -305.08% |
| Net Income (Continuing) | -57.49M | -70.66M | 335.27M | 4.57M | -62.71M | -37.06M | -66.63M | 27.78M | -110.08M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -150.31M | -108.53M | -17.64M | -16.21M | -9.37M | 5.37M | -5.83M | -6.77M | -6.4M |
| EPS (Diluted) | 1.10▲ 0% | -1.60▼ 245.5% | 14.40▲ 1000.0% | 0.20▼ 98.6% | -2.10▼ 1150.0% | -1.80▲ 14.3% | -2.40▼ 33.3% | 2.00▲ 183.3% | -46.00▼ 2400.0% |
| EPS Growth % | 152.38% | -245.45% | 1000% | -98.61% | -1150% | 14.29% | -33.33% | 183.33% | -2400% |
| EPS (Basic) | 1.10 | -1.60 | 14.90 | 0.20 | -2.10 | -1.80 | -2.40 | 2.00 | -46.00 |
| Diluted Shares Outstanding | 23.89M | 27.38M | 29.18M | 29.29M | 28.66M | 28.48M | 27.63M | 26.97M | 2.41M |
| Basic Shares Outstanding | 24.07M | 27.28M | 29.25M | 29.93M | 28.66M | 27.97M | 27.63M | 26.97M | 2.41M |
| Dividend Payout Ratio | 0.29% | - | 0.03% | - | - | - | - | - | - |
PRTC Balance Sheet
PureTech Health plc (PRTC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 198.11M | 259.79M | 168.84M | 414.35M | 501.81M | 386.19M | 347.2M | 386.26M | 305.02M |
| Cash & Short-Term Investments | 189.67M | 250.88M | 162.45M | 403.88M | 465.71M | 350.1M | 327.14M | 367.31M | 278.89M |
| Cash Only | 72.65M | 117.05M | 132.36M | 403.88M | 465.71M | 149.87M | 191.08M | 280.64M | 254.07M |
| Short-Term Investments | 117.03M | 133.83M | 30.09M | 0 | 0 | 200.23M | 136.06M | 86.67M | 24.83M |
| Accounts Receivable | 1.8M | 1.33M | 2.33M | 2.94M | 3.59M | 22.36M | 2.38M | 12.9M | 8.13M |
| Days Sales Outstanding | 1.01K | 29.61 | 97.76 | 128.61 | 131.27 | 3.9K | 260.43 | 975.48 | 636.93 |
| Inventory | -2.72M | -1.33M | 0 | 0 | 28M | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | 92.51 | - | - | - | - |
| Other Current Assets | 927K | 2.2M | 2.12M | 2.12M | -6.24M | 2.12M | 13.37M | 1.64M | 11.42M |
| Total Non-Current Assets | 141.74M | 181.98M | 772.33M | 575.64M | 444.2M | 316.45M | 346.77M | 216.38M | 229.69M |
| Property, Plant & Equipment | 6.86M | 8.32M | 43.84M | 42.87M | 43.94M | 37.24M | 19.36M | 15.13M | 11.5M |
| Fixed Asset Turnover | 0.09x | 1.97x | 0.20x | 0.19x | 0.23x | 0.06x | 0.17x | 0.32x | 0.41x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 601K |
| Intangible Assets | 3.31M | 3.08M | 625K | 899K | 987K | 831K | 906K | 601K | 0 |
| Long-Term Investments | 14.33M | 35.93M | 695.46M | 531.86M | 398.46M | 60.81M | 325.63M | 200.17M | 217.43M |
| Other Non-Current Assets | 117.1M | 134.2M | 32.27M | 531.87M | 399.27M | 278.38M | 879K | 476K | 166K |
| Total Assets | 339.85M▲ 0% | 441.76M▲ 30.0% | 941.18M▲ 113.1% | 989.99M▲ 5.2% | 946.01M▼ 4.4% | 702.65M▼ 25.7% | 693.97M▼ 1.2% | 602.63M▼ 13.2% | 534.71M▼ 11.3% |
| Asset Turnover | 0.00x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x | 0.01x |
| Asset Growth % | 13.76% | 29.99% | 113.05% | 5.19% | -4.44% | -25.72% | -1.23% | -13.16% | -11.27% |
| Total Current Liabilities | 273.86M | 265.76M | 139.2M | 180.92M | 226.13M | 96.89M | 51.37M | 41.39M | 46.31M |
| Accounts Payable | 3.39M | 4.64M | 11.1M | 8.87M | 11.35M | 26.5M | 14.64M | 5.52M | 3.07M |
| Days Payables Outstanding | 17.44 | 21.9 | 47.19 | - | 37.48 | 63.46 | 1.08K | - | - |
| Short-Term Debt | 7.46M | 12.01M | 1.46M | 26.45M | 5.5M | 7.5M | 3.7M | 4.11M | 8.67M |
| Deferred Revenue (Current) | 129.01M | 30.8M | 22.21M | 141.61M | 31.32M | 2.19M | -29.47M | 0 | 0 |
| Other Current Liabilities | 121.04M | 207.08M | 92.45M | -529K | 152.01M | 29.4M | 29.64M | 27.18M | 31.54M |
| Current Ratio | 0.72x | 0.98x | 1.21x | 2.29x | 2.22x | 3.99x | 6.76x | 9.33x | 6.59x |
| Quick Ratio | 0.73x | 0.98x | 1.21x | 2.29x | 2.10x | 3.99x | 6.76x | 9.33x | 6.59x |
| Cash Conversion Cycle | - | - | - | - | 186.3 | - | - | - | - |
| Total Non-Current Liabilities | 1.99M | 9.03M | 151.58M | 155.53M | 135.72M | 58.17M | 184.37M | 153.31M | 182.73M |
| Long-Term Debt | 0 | 357K | 0 | 14.82M | 14.26M | 10.24M | 0 | 0 | 0 |
| Capital Lease Obligations | 410K | 357K | 34.91M | 32.09M | 29.04M | 24.16M | 18.25M | 14.67M | 11.09M |
| Deferred Tax Liabilities | 4.4M | 6.43M | 115.44M | 108.63M | 89.77M | 19.64M | 52.46M | 0 | 0 |
| Other Non-Current Liabilities | 1.42M | 876K | 0 | -1K | 2.66M | 4.13M | 113.66M | 138.64M | 171.64M |
| Total Liabilities | 275.85M | 274.79M | 290.78M | 336.45M | 361.86M | 155.06M | 235.74M | 194.7M | 229.03M |
| Total Debt | 7.46M | 12.37M | 39.3M | 76.62M | 52.75M | 46.87M | 25.34M | 22.36M | 19.76M |
| Net Debt | -65.19M | -104.68M | -93.06M | -327.26M | -413.68M | -102.99M | -165.74M | -258.28M | -234.31M |
| Debt / Equity | 0.12x | 0.07x | 0.06x | 0.12x | 0.09x | 0.09x | 0.06x | 0.05x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -6.85x | -4.60x | 117.29x | 19.02x | 4.13x | -50.04x | -1.23x | 3.37x | -1.42x |
| Total Equity | 64M▲ 0% | 166.97M▲ 160.9% | 650.4M▲ 289.5% | 653.54M▲ 0.5% | 584.15M▼ 10.6% | 547.59M▼ 6.3% | 458.23M▼ 16.3% | 407.93M▼ 11.0% | 305.68M▼ 25.1% |
| Equity Growth % | -30.75% | 160.91% | 289.53% | 0.48% | -10.62% | -6.26% | -16.32% | -10.98% | -25.07% |
| Book Value per Share | 2.68 | 6.10 | 22.29 | 22.32 | 20.38 | 19.23 | 16.58 | 15.13 | 126.95 |
| Total Shareholders' Equity | 214.3M | 275.51M | 668.04M | 669.75M | 593.51M | 542.22M | 464.07M | 414.71M | 312.07M |
| Common Stock | 4.68M | 5.38M | 5.41M | 5.42M | 5.44M | 5.46M | 5.46M | 4.86M | 4.86M |
| Retained Earnings | -127.87M | -167.69M | 254.44M | 260.43M | 199.87M | 149.52M | 83.82M | 32.49M | 61.27M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | -26.49M | -44.63M | -46.86M | -41.15M |
| Accumulated OCI | -3.88M | -6.07M | -18.28M | -23.58M | -39.61M | -14.39M | 129.15M | 133.96M | 182K |
| Minority Interest | -150.31M | -108.53M | -17.64M | -16.21M | -9.37M | 5.37M | -5.83M | -6.77M | -6.4M |
PRTC Cash Flow Statement
PureTech Health plc (PRTC) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -88.69M | -72.8M | -98.16M | -131.83M | -158.27M | -178.79M | -105.92M | -134.37M | -85.33M |
| Operating CF Margin % | -13644.31% | -444.66% | -1129.79% | -1580.47% | -1586.07% | -8554.64% | -3180.69% | -2783.12% | -1831.51% |
| Operating CF Growth % | -52.82% | 17.92% | -34.84% | -34.3% | -20.06% | -12.96% | 40.76% | -26.86% | 36.5% |
| Net Income | -70.7M | -70.66M | 366.06M | 4.57M | -62.71M | -37.06M | -65.7M | 27.78M | -110M |
| Depreciation & Amortization | 2.1M | 2.78M | 6.67M | 6.64M | 7.29M | 8.89M | 4.93M | 3.57M | 3.36M |
| Stock-Based Compensation | 11.85M | 12.64M | 14.47M | 10.72M | 13.95M | 14.7M | 4.42M | 22.85M | 0 |
| Deferred Taxes | -116.81M | -19.42M | -546.61M | -151.35M | -112.61M | -70.12M | 0 | 0 | -2.74M |
| Other Non-Cash Items | 81.9M | -8.1M | 46.23M | 6.11M | -5.05M | -111.12M | -67.09M | -178.34M | 27.18M |
| Working Capital Changes | 2.97M | 9.96M | 15.03M | -8.53M | 861K | 15.92M | 17.52M | -10.24M | -3.13M |
| Change in Receivables | -1.67M | 467K | 747K | -529K | -617K | -7.73M | 9.75M | 629K | -236.55K |
| Change in Inventory | 0 | 0 | 0 | 0 | -103K | 0 | 0 | 0 | 0 |
| Change in Payables | 5.24M | 5.09M | 11.17M | 605K | 8.34M | 22.03M | 3.84M | -9.7M | -1.03M |
| Cash from Investing | 83.68M | -39.65M | 63.66M | 364.48M | 197.38M | -107.22M | 68.99M | 240.89M | 63.44M |
| Capital Expenditures | -2.17M | -4.49M | -12.54M | -5.42M | -5.66M | -2.18M | -245K | -11K | -6.01K |
| CapEx % of Revenue | 334% | 27.43% | 144.31% | 65.03% | 56.73% | 104.11% | 7.36% | 0.23% | 0.13% |
| Acquisitions | -16.34M | -13.39M | -16.04M | -10M | 321K | -20.44M | -13.78M | -105.97M | 269.63K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -16.34M | 125K | 191K | 350K | -14.91M | 416K | 865K | 255K | 49.11K |
| Cash from Financing | 14.7M | 156.89M | 49.91M | 38.87M | 22.73M | -29.83M | 78.14M | -16.96M | -6.34M |
| Debt Issued (Net) | 2.45M | 5.96M | 1.43M | 39.79M | 2.21M | 393K | -3.34M | -3.39M | 0 |
| Equity Issued (Net) | 12.33M | -35K | 50.27M | 1.99M | -13.33M | -26.15M | -18.5M | -106.66M | -1.95M |
| Dividends Paid | -91K | -8K | -112K | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -66K | -35K | -1.28M | 0 | 0 | -26.49M | -19.65M | -107.56M | -2.06M |
| Other Financing | 0 | 150.96M | -1.68M | -2.91M | 33.84M | -4.07M | 99.98M | 93.1M | -4.39M |
| Net Change in Cash | 9.69M▲ 0% | 44.4M▲ 358.2% | 15.31M▼ 65.5% | 271.52M▲ 1673.6% | 61.83M▼ 77.2% | -315.84M▼ 610.8% | 41.22M▲ 113.0% | 89.56M▲ 117.3% | -28.22M▼ 131.5% |
| Free Cash Flow | -90.86M▲ 0% | -77.29M▲ 14.9% | -110.69M▼ 43.2% | -137.25M▼ 24.0% | -163.94M▼ 19.4% | -180.97M▼ 10.4% | -106.16M▲ 41.3% | -134.38M▼ 26.6% | -85.34M▲ 36.5% |
| FCF Margin % | -13978.31% | -472.09% | -1274.1% | -1645.5% | -1642.8% | -8658.76% | -3188.05% | -2783.35% | -1831.64% |
| FCF Growth % | -47.24% | 14.94% | -43.23% | -23.99% | -19.44% | -10.39% | 41.34% | -26.58% | 36.5% |
| FCF per Share | -3.80 | -2.82 | -3.79 | -4.69 | -5.72 | -6.36 | -3.84 | -4.98 | -35.44 |
| FCF Conversion (FCF/Net Income) | -2.87x | 1.67x | -0.23x | -22.03x | 2.61x | 3.55x | 1.61x | -2.51x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRTC Key Ratios
PureTech Health plc (PRTC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -38.05% | 39.47% | -37.8% | 103.05% | 0.92% | -9.79% | -8.9% | -13.06% | 12.36% | -30.76% |
| Return on Invested Capital (ROIC) | -156.94% | -491.73% | -255.4% | -32.78% | -20.29% | -45.31% | -48.18% | -29.75% | -46.17% | -66.87% |
| Gross Margin | 64.57% | -10828.46% | -372.8% | -888.12% | 100% | -1007.03% | -6546.17% | -48.14% | 26.04% | 100% |
| Net Margin | -1101.15% | 4749.08% | -266.65% | 4847.42% | 71.75% | -606.85% | -2409.33% | -1972.88% | 1108.33% | -2355.42% |
| Debt / Equity | 0.08x | 0.12x | 0.07x | 0.06x | 0.12x | 0.09x | 0.09x | 0.06x | 0.05x | 0.06x |
| Interest Coverage | -11.22x | -6.85x | -4.60x | 117.29x | 19.02x | 4.13x | -50.04x | -1.23x | 3.37x | -1.42x |
| FCF Conversion | 1.19x | -2.87x | 1.67x | -0.23x | -22.03x | 2.61x | 3.55x | 1.61x | -2.51x | 0.78x |
| Revenue Growth | -62.26% | -85.33% | 2418.62% | -46.93% | -3.99% | 19.64% | -79.06% | 59.33% | 44.98% | -3.5% |
PRTC Frequently Asked Questions
PureTech Health plc (PRTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
PureTech Health plc (PRTC) reported $9.0M in revenue for fiscal year 2025. This represents a 13% increase from $7.9M in 2012.
PureTech Health plc (PRTC) saw revenue decline by 3.5% over the past year.
PureTech Health plc (PRTC) reported a net loss of $56.0M for fiscal year 2025.
Dividend & Returns
PureTech Health plc (PRTC) has a return on equity (ROE) of -30.8%. Negative ROE indicates the company is unprofitable.
PureTech Health plc (PRTC) had negative free cash flow of $218.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More PRTC
PureTech Health plc (PRTC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates